Oct 1 |
BioCryst Secures Major US Health Department Influenza Drug Deal
|
Oct 1 |
BioCryst secures $69m contract from US to supply RAPIVAB for influenza
|
Sep 30 |
BioCryst Pharmaceuticals awarded $69M influenza treatment contract from U.S. HHS
|
Sep 30 |
With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns
|
Sep 30 |
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
|
Sep 29 |
BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
|
Sep 17 |
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
|
Sep 12 |
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
|
Sep 6 |
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
|
Sep 5 |
BioCryst Pharmaceuticals names Donald Fong as chief medical officer
|